Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Clinical Professor Russell S. Scott

BMedSc MB ChB(Otago) PhD(Monash) FRACP

Lipids and Diabetes Research
Christchurch Hospital
Private Bag 4710
Christchurch
New Zealand

Email russell.scott@cdhb.govt.nz

Current Roles

  • Clinical Professor of Medicine, University of Otago, Christchurch, New Zealand
  • Director, Lipid and Diabetes Research, Christchurch
  • Christchurch Physician in Charge, Lipid Disorders and Cardiovascular Prevention, Canterbury District Health Board
  • Physician, Diabetes Services, Canterbury District Health Board
  • Physician, Internal Medicine, Canterbury District Health Board
  • Consultant, MedLab South

Research Interests

  • Prevention and treatment of type 1 Diabetes Mellitus
  • Adipocyte function and Insulin resistance
  • Lipid disorders and CVD
  • Endothelial function and endocrine regulation
  • Diabetes Epidemiology and health outcomes

Top 10 Publications

  • Scott R.S. and Burger H.G. Inhibin is absent from azoospermic semen of infertile men. In Nature 285: 246 247 (1980). Also profiled in Yearbook of Endocrinology, Mosby (1981).
  • Scott R.S., Brown L.J., Darlow B.A., Forbes L.V. and Moore M.P. Temporal variations in incidence of IDDM in New Zealand. In Diabetes Care 15:895-899 (1992).
  • Forbes L.V., Scott R.S., Brown L.J. and Darlow B.A. Immunogenetic, clinical and demographic characterisation of childhood type I diabetes in New Zealand. In Diabetes Care 18: 1428-1433 (1995).
  • Florkowski C.M., Scott R.S., Moir C.L. and Graham P.J. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. In Diabetic Medicine 15:386-392 (1998).
  • Willis J.A., Scott R.S., Darlow B.A, Lewy H., Ashkenazi I., Laron Z., Seasonality of Birth and Onset of Clinical Disease in Children and Adolescents (0 � 19 years) with Type 1 Diabetes Mellitus in Canterbury, New Zealand. In Journal of Pediatric Endocrinology & Metabolism, 15: 645 � 647 (2002). Also, subject of editorial comment by Z Laron in Journal of Pediatric Endocrinology & Metabolism 15:573-575 (2002).
  • Phillips P., Karrasch J., Scott R., Wilson D., Moses R. Acarbose improves glycaemic control in overweight Type 2 diabetic patients insufficiently treated with metformin. In Diabetes Care, 26:269-273 (2003).
  • Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott R.S. The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. In Diabetologia 47: 1838-1846 (2004).
  • The FIELD Study Investigators ( R. Scott, writing committee and Executive Committee member). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology Dec 1;3:9, (2004)
  • Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott R.S, Frampton CM. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179:201-6 (2005)
  • Scott RS, Best J, Forder P, Taskinen M.R., Simes J, Barter P, Keech A (The FIELD study investigators). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate. Cardiovascular Diabetology Aug 22;4:13 ( 2005)

^ Top of page

Publications

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4

Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., & Scott, R. S. (2012). Pharmacokinetic comparison of a generic coenzyme Q10 solubilizate and a formulation with soybean phytosterols. Phytotherapy Research, 26, 1092-1096. doi: 10.1002/ptr.3667

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012). A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. American Journal of Hypertension, 25(2), 261-270. doi: 10.1038/ajh.2011.209

Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., … Scott, R., … for the SPARCL Investigators. (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Archives of Neurology, 68(10), 1245-1251. doi: 10.1001/archneurol.2011.146

Young, J. M., Molyneux, S. L., Reinheimer, A. M., Florkowski, C. M., Frampton, C. M., Scott, R., & George, P. M. (2011). Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis, 218(1), 188-193. doi: 10.1016/j.atherosclerosis.2011.04.034

Journal - Research Article

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4

Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., & Scott, R. S. (2012). Pharmacokinetic comparison of a generic coenzyme Q10 solubilizate and a formulation with soybean phytosterols. Phytotherapy Research, 26, 1092-1096. doi: 10.1002/ptr.3667

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012). A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. American Journal of Hypertension, 25(2), 261-270. doi: 10.1038/ajh.2011.209

Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., … Scott, R., … for the SPARCL Investigators. (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Archives of Neurology, 68(10), 1245-1251. doi: 10.1001/archneurol.2011.146

Young, J. M., Molyneux, S. L., Reinheimer, A. M., Florkowski, C. M., Frampton, C. M., Scott, R., & George, P. M. (2011). Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis, 218(1), 188-193. doi: 10.1016/j.atherosclerosis.2011.04.034

Meininger, G. E., Scott, R., Alba, M., Shentu, Y., Luo, E., Amin, H., … Goldstein, B. J. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care, 34(12), 2560-2566. doi: 10.2337/dc11-1200

Sorrenson, B., Suetani, R. J., Bickley, V. M., George, P. M., Williams, M. J. A., Scott, R. S., & McCormick, S. P. A. (2011). An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations. Biochemical & Biophysical Research Communications, 409(3), 400-405. doi: 10.1016/j.bbrc.2011.05.006

King, R. I., Florkowski, C. M., Yeo, J., Walmsley, T. A., Shand, B. I., Scott, R. S., & George, P. M. (2011). What is the best predictor of the atherogenic LDL subclass phenotype ‘pattern B’ in patients with type 2 diabetes mellitus? Annals of Clinical Biochemistry, 48(2), 166-169. doi: 10.1258/acb.2010.010185

Miller, L. J., Willis, J. A., Pearce, J., Barnett, R., Darlow, B. A., & Scott, R. S. (2011). Urban-rural variation in childhood type 1 diabetes incidence in Canterbury, New Zealand, 1980 to 2004. Health & Place, 17(1), 248-256. doi: 10.1016/j.healthplace.2010.10.010

Scott, R., Donoghoe, M., Watts, G. F., O'Brien, R., Pardy, C., Taskinen, M.-R., … Manning, P., … Keech, A. C. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10, 102. doi: 10.1186/1475-2840-10-102

MacLean, A., McKenney, J. M., Scott, R., Brinton, E., Bays, H. E., Mitchel, Y. B., … Maccubbin, D. L. (2011). Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology, 18(1), 37-45.

Eady, S., Wallace, A., Willis, J., Scott, R., & Frampton, C. (2011). Consumption of a plant sterol-based spread derived from rice bran oil is effective at reducing plasma lipid levels in mildly hypercholesterolaemic individuals. British Journal of Nutrition, 105(12), 1808-1818. doi: 10.1017/S0007114510005519

King, R. I., Scott, R. S., Florkowski, C. M., Laurie, A. D., Reid, N., & George, P. M. (2010). Homozygous familial hypercholesterolaemia and treatment by LDL apheresis [Clinical correspondence]. New Zealand Medical Journal, 123(1319). Retrieved from http://journal.nzma.org.nz/journal/123-1319/4230/content.pdf

Monro, J. A., Wallace, A., Mishra, S., Eady, S., Willis, J. A., Scott, R. S., & Hedderley, D. (2010). Relative glycaemic impact of customarily consumed portions of eighty-three foods measured by digesting in vitro and adjusting for food mass and apparent glucose disposal. British Journal of Nutrition, 104(3), 407-417. doi: 10.1017/S0007114510000589

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Shand, B. I., Scott, R. S., & Chambers, S. T. (2010). Fibrates plus betaine: A winning combination? [Viewpoint]. New Zealand Medical Journal, 123(1324). Retrieved from http://journal.nzma.org.nz/journal/123-1324/4389/content.pdf

Lewis, J. G., Borowski, K. K., Shand, B. I., George, P. M., & Scott, R. S. (2010). Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: A cross-sectional study of 1137 subjects. Hormone & Metabolic Research, 42(4), 274-279. doi: 10.1055/s-0029-1243260

Wallace, A., Eady, S., Miles, M., Martin, H., McLachlan, A., Rodier, M., Willis, J., Scott, R., & Sutherland, J. (2010). Demonstrating the safety of manuka honey UMF® 20+ in a human clinical trial with healthy individuals. British Journal of Nutrition, 103(7), 1023-1028. doi: 10.1017/S0007114509992777

Simes, J., Voysey, M., O'Connell, R., Glasziou, P., Best, J. D., Scott, R., … for the FIELD Study Investigators, including Manning, P. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS ONE, 5(1), e8580. doi: 10.1371/journal.pone.0008580

Wallace, A. J., Eady, S. L., Willis, J. A., Scott, R. S., Monro, J. A., & Frampton, C. M. (2009). Variability in measurements of blood glucose response to foods in human subjects is not reduced after a standard breakfast. Nutrition Research, 29(4), 238-243. doi: 10.1016/j.nutres.2009.03.003

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Scott, R. S., Richards, A. M., Fink, J. N., & Chambers, S. T. (2009). Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovascular Drugs & Therapy, 23(5), 395-401. doi: 10.1007/s10557-009-6188-1

Lewis, J. G., Shand, B. I., Frampton, C. M., Elder, P. A., & Scott, R. S. (2009). Plasma levels of sex hormone-binding globulin, corticosteroid-binding globulin and cortisol in overweight subjects who develop impaired fasting glucose: A 3-year prospective study. Hormone & Metabolic Research, 41(3), 255-259. doi: 10.1055/s-0028-1087190

Miller, L. J., Pearce, J., Barnett, R., Willis, J., Darlow, B. A., & Scott, R. S. (2009). Is population mixing associated with childhood type 1 diabetes in Canterbury, New Zealand? Social Science & Medicine, 68(4), 625-630. doi: 10.1016/j.socscimed.2008.11.027

Elmslie, J. L., Porter, R. J., Joyce, P. R., Hunt, P. J., Shand, B. I., & Scott, R. S. (2009). Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Australian & New Zealand Journal of Psychiatry, 43(1), 53-60. doi: 10.1080/00048670802534341

Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Tse, D., … on behalf of the Fenofibrate Intervention and Event Lowering in Diabete (FIELD) Study Investigators, including Manning, P. (2009). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care, 32(3), 493-498. doi: 10.2337/dc08-1543

Shand, B. I., Scott, R. S., Lewis, J. G., Elder, P. A., & Frampton, C. M. (2009). Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: A 3-year prospective study. International Journal of Obesity, 33(11), 1274-1279. doi: 10.1038/ijo.2009.169

More publications...